Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Ligand Pharmaceuticals Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Pharmaceutical Preparations
No intraday reading yet this session.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of LGND revenue | Skew |
|---|---|---|---|
| TVTXTravere | 16.00% | 29.29% | 0.5× |
| OBIOOrchestra BioMed Holdings, Inc. | 17.00% | 2.12% | 8.0× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“As of December 31, 2025, Recordati was the largest individual marketer and payor of our financial royalty assets, representing 54% of these assets.”
$145M relationship
basisLGND fy2025 · closed 2025-12 $268M
FILING10-K0000886163-26-000006cik 0000886163
“In repayment of the Investment Amount, we will remit 17.0% of revenues related to the Products until an annual total of $17.0 million has been remitted to Ligand, thereafter we will remit (a) 4.0% of revenues related to the Primary Product in the field of hypertension treatment and (b) 4.0% of revenues related to the Secondary Product in the field of coronary artery treatment.”
$6M relationship8.0× more of OBIO’s book than LGND’s
basisOBIO fy2025 · closed 2025-12 $33MLGND fy2025 · closed 2025-12 $268M
“We have otherwise primarily funded our business through the sale of our capital stock and through the entry into the royalty, license and termination agreement ("RLT Agreement") with Takeda Company Limited ("Takeda"), which resulted in a one-time up-front payment of $196.0 million in 2021 and the entry into a Royalty Monetization Agreement (the "Ligand Agreement") with Ligand Pharmaceuticals Incorporated ("Ligand"), which resulted in a one-time up-front payment of $30.0 million in 2023.”
FILING10-K0001628280-26-019438cik 0001636651disclosed by OVID
“We granted to Ligand a non-exclusive, sublicensable, worldwide license, under our improvements to Ligand's licensed technology, to develop, manufacture and sell products containing lasofoxifene for topical and other non-oral uses.”
FILING10-K0001193125-26-134565cik 0001620463disclosed by LONA
“We also have commitments under our supply agreement with Hovione for Captisol purchases.”
FILING10-K0000886163-25-000012cik 0000886163
“We have a license agreement with Pelthos for Zelsuvmi (berdazimer) topical gel, 10.3%, the first and only at-home treatment for molluscum contagiosum infections in adults and pediatric patients one year of age and older.”
FILING10-K0000886163-26-000006cik 0000886163
“In early 2012, we licensed the world-wide rights to Filspari (sparsentan) to Travere Therapeutics.”
FILING10-K0000886163-26-000006cik 0000886163
“Under the Ligand Agreement, we received from Ligand an exclusive (even as to Ligand), sublicensable license, under relevant know-how and certain patents owned or in-licensed by Ligand, to develop, manufacture and sell Licensed Products for oral use in the Licensed Territory.”
FILING10-K0001193125-26-134565cik 0001620463disclosed by LONA
“As partial consideration for the grant of the rights and licenses to the Company under the Master License Agreement, the Company issued to Ligand at the closing of the Company's initial public offering ("IPO") 3,655,964 shares of its common stock having an estimated aggregate value of $ 29.2 million.”
FILING10-K0001193125-26-046876cik 0001607678disclosed by VKTX
“We supply Captisol to, and receive royalties from, Acrotech Biopharma for sales of Evomela in the United States, and CASI Pharmaceuticals for sales in China.”
FILING10-K0000886163-26-000006cik 0000886163
“On September 24, 2025, we invested $7 million in strategic capital to purchase economic rights from Arecor Limited ("Arecor"), with an additional $1 million in deferred consideration payable in two equal parts at the six- and twelve-month anniversaries of the transaction closing date.”
FILING10-K0000886163-26-000006cik 0000886163
“We have a license agreement with Baxter, related to Nexterone, a Captisol-enabled formulation of amiodarone, which is marketed in the United States and Canada.”
FILING10-K0000886163-26-000006cik 0000886163
“We supply Captisol to, and receive royalties from, Acrotech Biopharma for sales of Evomela in the United States, and CASI Pharmaceuticals for sales in China.”
FILING10-K0000886163-26-000006cik 0000886163
“In February 2025, we entered into a royalty financing agreement with Castle Creek Biosciences, Inc., a late-stage cell and gene therapy company, to support Castle Creek's D-Fi (FCX-007) Phase 3 clinical study.”
FILING10-K0000886163-26-000006cik 0000886163
“Contract revenue and other revenue increased by $9.5 million primarily due to milestone payments earned from Verona Pharma upon the approval and commercial launch of Ohtuvayre.”
FILING10-K0000886163-25-000012cik 0000886163
“In May 2024, we, and certain wholly-owned subsidiaries, entered into a Purchase and Sale Agreement (the "Ligand Purchase Agreement") with Ligand Pharmaceuticals Incorporated ("Ligand") for the sale to Ligand of (i) 31.875% of the development, regulatory and commercial milestone payments we were then eligible to receive under our agreements with BMS, UroGen, Gilead, Merck and Incyte, (the "Covered License Agreements") (ii) 18.75% of the royalties we receive under the Covered License Agreements; and (iii) a 2.625% synthetic royalty on worldwide net sales of botensilimab and balstilimab (collectively the "Purchased Assets").”
FILING10-K0001193125-26-108632cik 0001098972disclosed by AGEN
“The MSA between Ligand and the Company provides Ligand, Ligand affiliated parties or third-party licensees with an ability to source commercial or developmental supply of API, while also providing the Company with the associated economics of the supply of such material.”
FILING10-K0001919246-26-000013cik 0001919246disclosed by PTHS
“In May 2024, we entered into the Agenus Agreement to support BOT/BAL clinical development.”
FILING10-K0000886163-26-000006cik 0000886163
“This unique technology has enabled 17 FDA-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter's Nexterone, and Acrotech Biopharma's Evomela.”
FILING10-K0000886163-26-000006cik 0000886163
“In July 2021, Jazz announced the U.S. launch of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), previously referred to as JZP458.”
FILING10-K0000886163-26-000006cik 0000886163
“Our commercialization partner, Alvogen, launched the product in June 2020 in the United States.”
FILING10-K0000886163-26-000006cik 0000886163
“Travere has also partnered with Chugai Pharmaceuticals to develop and commercialize Filspari in Japan and other Asian countries.”
FILING10-K0000886163-26-000006cik 0000886163
“In February 2024, Travere and its partner CSL Vifor received approval for Filspari for the treatment of IgAN in Europe.”
FILING10-K0000886163-26-000006cik 0000886163
“On July 31, 2025, Ligand invested $25 million in strategic capital to fund Orchestra BioMed Holdings, Inc.'s ("Orchestra" or "Orchestra Biomed") late-stage partnered cardiology programs, consisting of a $20 million cash payment paid at closing and an additional $5 million to purchase shares of Orchestra's common stock in an equity private placement at the price of $2.75 per share (the price of Orchestra's common stock at its last public offering).”
FILING10-K0000886163-26-000006cik 0000886163
Watchlist prices, news filtered to it, and its next report on your desk.
FILING10-K0001104659-26-026754cik 0001814114disclosed by OBIO
Ligand Pharmaceuticals Inc has 6 disclosed suppliers and 27 disclosed customers. Each one is named in an SEC filing, either Ligand Pharmaceuticals Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
LGND (Ligand Pharmaceuticals Inc) has 6 disclosed suppliers and 27 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: SNY −2.03%, in the industrials bundle.